2008 a Record Year for Gerresheimer



    DUSSELDORF, Germany, April 29 /CNW/ -

    
    - Strong Focus on the Markets of Pharma & Life Science

    - Annual General Meeting Passes Dividend of EUR0.40 per Share
    

    The Annual General Meeting of Gerresheimer AG today passed an unchanged
dividend of EUR0.40 per share following the record year in 2008.
    The Company finished the financial year 2008 with record results.
Gerresheimer achieved sales of EUR1.06 billion (prior year EUR957.7m) and
operating results (adjusted EBITDA) of EUR206.4m (prior year EUR181.6m).
    At the Annual General Meeting in Dusseldorf the CEO Dr. Axel Herberg
summarized the highlights of the financial year 2008: "We have achieved record
levels in terms of sales and earnings. Gerresheimer is on a good course and
will show itself to be very robust even in times of crisis."
    The shareholders approved the actions of the members of the Company's
Supervisory Board and Management Board for the financial year 2008 and, as in
the prior year, passed a dividend payment of EUR0.40 per share.
    With share capital representation of 59.44% the Annual General Meeting
passed the following resolutions:

    ITEM 2: Appropriation of net earnings for the financial year 2008:
    (99.99% of votes in favor)

    ITEM 3: Approval of the actions of the Management Board members for the
financial year 2008:
    (100% of votes in favor)

    ITEM 4: Approval of the actions of the Supervisory Board members for the
financial year 2008:
    (100% of votes in favor)

    ITEM 5: Supplementary election to the Supervisory Board of Mr. Theodor
Stuth, Auditor and Certified Tax Advisor, Neuss:
    (100% of votes in favor)

    ITEM 6: Election of the auditor for the financial year 2009:
    (99.99% of votes in favor)

    The speech is available on http://www.gerresheimer.com/en/press.html.
    About Gerresheimer

    Gerresheimer employs around 10,000 people in 42 locations in Europe, 
America and Asia. In the financial year 2008, worldwide sales totalled
EUR1.06bn. The product portfolio ranges from pharmaA-ceuA-tical vials made of
glass and plastic through to complex drug-delivery systems for the pharma &
life science industry. These include sterile syringes, inhalers and other
system-based approaches for safe dosage and application of medications. The
Group enjoys a leading position in markets which are characterised by high
technical and regulatory barriers.(WKN: 587300)





For further information:

For further information: Contact Press: Burkhard Lingenberg, Director
Corporate Communication & Marketing, Phone +49-211-6181-250, Fax
+49-211-6181-241, e-mail b.lingenberg@gerresheimer.com; Contact Investor
Relations: Anke Linnartz, Director Corporate Investor Relations, Phone
+49-211-6181-314, Fax  +49-211-6181-121, e-mail a.linnartz@gerresheimer.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890